[1」杨文涛,薛卫成,卞修武,等.肿瘤病理诊断规范(乳腺癌).中华病理学杂志,2016,45(8):525-528.
[2」《乳腺癌 HER2 检测指南(2019 版)》编写组.乳腺癌 HER2 检测指南(2019 版).中华病理学杂志,2019,48(3):169-175.
[ 3 ] WOLFF AC, SOMERFIELD MR, DOWSETT M, et al. Human epidermal growth factor receptor 2 testing in breastcancer: ASCO-College of American Pathologists guideline update. J Clin Oncol, 2023, 41 (22): 3867-3872.
[ 4 ] TARANTINO P, VIALE G, PRESS MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis,and management of HER2-low breast cancer. Ann Oncol, 2023, 34 (8): 645-659.
[ 5 ] ALLISON KH, HAMMOND M, DOWSETT M, et al. Estrogen and progesterone receptor testing in breast cancer:ASCO/CAP guideline update. J Clin Oncol, 2020, 38 (12): 1346-1366.
[6 ] NIELSEN TO, LEUNG S, RIMM DL, et al. Assessment of Ki67 in breast cancer: Updated recommendations from theInternational Ki67 in Breast Cancer Working Group. J Natl Cancer Inst, 2021, 113 (7): 808-819.
[7]《乳腺癌新辅助治疗的病理诊断专家共识(2020版)》编写组.乳腺癌新辅助治疗的病理诊断专家共识(2020版).中华病理学杂志,2020,49 (4):296-304.
[ 8 ] HURVITZ SA, MARTIN M, JUNG KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epider-mal growth factor receptor 2-positive breast cancer: Three-year outcomes from the phase IMl KRISTINE Study. J ClinOncol, 2019, 37 (25): 2206-2216.
[9] VAN RAMSHORST MS, VAN DER VOORT A, VAN WERKHOVEN ED, et al. Neoadjuvant chemotherapy with orwithout anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multi-centre, open-label, randomised, phase 3 trial. Lancet Oncol, 2018, 19 (12): 1630-1640.
[ 10 ] GIANNI L, PIENKOWSKI T, IM YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patientswith locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17 (6): 791-800.
[ 11 ] HUANG L, PANG D, YANG HJ, et al. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer:Final analysis of the randomized phase Ill PEONY trial. Nat Commun, 2024, 15 (1): 2153.
[12 ] WU J, JIANG Z, LIU Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer(PHEDRA): A double-blind, randomized phase 3 trial. BMC Med, 2022, 20 (1): 498.
[13] UNTCH M, JACKISCH C, SCHNEEWEISS A, et al. NAB-paclitaxel improves disease-free survival in early breast
[14] VON MINCKWITZ G, HUANG CS, MANO MS, et al. Trastuzumab emtansine for residual invasive HER2-positivebreast cancer. N Engl J Med, 2019, 380 (7): 617-628.
[15] MARTIN M, HOLMES FA, EJLERTSEN B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol, 2017, 18 (12): 1688-1700.
[16] ZHANG L, WU ZY, LI J, et al. Neoadjuvant docetaxel plus carboplatin vs. epirubicin plus cyclophosphamide fol-lowed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter. randomizedcontrolled, open-label phase II trial. Int J Cancer, 2022, 150 (4): 654-662.
[17] SCHMID P, CORTES J, PUSZTAI L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med,2020, 382 (9): 810-821.
[18 ] TUTT A, GARBER JE, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCAl-or BRCA2-mutated breastcancer. N Engl J Med, 2021, 384 (25): 2394-2405.
[19] SPARANO JA, GRAY RJ, MAKOWER DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay inbreast cancer. N Engl J Med, 2018, 379 (2): 111-121.
[ 20] KALINSKY K, BARLOW WE, GRALOW JR, et al. 21-gene assay to informm chemotherapy benefit in node-positivebreast cancer. N Engl J Med, 2021, 385 (25): 2336-2347.
[21] CARDOSO F, VAN'T VEER LJ, BOGAERTS J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med, 2016, 375 (8): 717-729.
[22 ] VON MINCKWITZ G, PROCTER M, DE AZAMBUJA E, et al. Adjuvant pertuzumab and trastuzumab in earlyHER2-positive breast cancer. N Engl J Med, 2017, 377 (2): 122-131.
[ 23 ] LI J, ZHOU J, WANG H, et al. Trends in disparities and transitions of treatment in patients with early breast cancerin China and the US, 2011 to 2021. JAMA Netw Open, 2023, 6 (6): e2321388.
[ 24 ] JONES SE, COLLEA R, PAUL D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patientswith HER2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. Lancet Oncol, 2013, 14(11): 1121-1128.
[25 ] TOLANEY SM, GUO H, PERNAS S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumabtrial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 2019, 37 (22):1868-1875.
[26] MACKEY JR, PIENKOWSKI T, CROWN J, et al. Long-term outcomes after adjuvant treatment of sequentialversus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005randomized trial. Ann Oncol, 2016, 27 (6): 1041-1047. 
[ 27] YU KD, YE FG, HE M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-nega-tive breast cancer: A phase 3 randomized clinical trial. JAMA Oncol, 2020, 6 (9): 1390-1396.
[ 28 ] JONES S, HOLMES FA, O'SHAUGHNESSY J, et al. Docetaxel with cyclophosphamide is associated with an over-all survival benefit compared with doxorubicin and cyclophosphamide: 7-Year Follow-Up of US Oncology ResearchTrial 9735. J Clin Oncol, 2009, 27 (8): 1177-1183.
[29 ] NITZ U, GLUZ O, CLEMENS M, et al. West german study planb trial: Adjuvant four cycles of epirubicin andcyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative earlybreast cancer. J Clin Oncol, 2019, 37 (10): 799-808.
[ 30 ] WANG X, WANG SS, HUANG H, et al. Effect of capecitabine maintenance therapy using lower dosage and higherfrequency vs. observation on disease-free survival among patients with early-stage triple-negative breast cancer whohad received standard treatment: The SYSUCC-001 randomized clinical trial. JAMA, 2021, 325 (1): 50-58.
[ 31 ] LI J, JIANG Z. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: Stratificationand classification. Cancer Biol Med, 2022, 19 (6): 769-773.
[32] REGAN MM, NEVEN P, GIOBBIE-HURDER A, et al. Assessment of letrozole and tamoxifen alone and insequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 ran-domised clinical trial at 8.1 years median follow-up. Lancet Oncol, 2011, 12 (12): 1101-1108.
[ 33 ] GOSS PE, INGLE JN, PATER JL, et al. Late extended adjuvant treatment with letrozole improves outcome inwomen with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol, 2008, 26 (12): 1948-1955.
[ 34 ] TJAN-HEIJNEN V, VAN HELLEMOND I, PEER P, et al. Extended adjuvant aromatase inhibition after sequentialendocrine therapy (DATA): A randomised, phase 3 trial. Lancet Oncol, 2017, 18 (11): 1502-1511.
[ 35 ] JOHNSTON S, HARBECK N, HEGG R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (MonarchE). J Clin Oncol, 2020, 38 (34): 3987-3998.
[ 36 ] SLAMON D, LIPATOV O, NOWECKI Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl JMed, 2024, 390 (12): 1080-1091.
[ 37 ] GOSS PE, INGLE JN, PRITCHARD KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl JMed, 2016, 375 (3): 209-219.
[ 38 ] PAGANI O, FRANCIS PA, FLEMING GF, et al. SOFT and TEXT Investigators and Intermational Breast CancerStudy Group: Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies forpremenopausal women: Results from TEXT and SOFT. J Clin Oncol, 2020, 38 (12): 1293-1303.
[ 39 ] FRANCIS PA, REGAN MM, FLEMING GF, et al. Adjuvant ovarian suppresion in premenopausal breast cancer. NEngl J Med, 2015, 372 (5): 436-446.
[ 40 ] PAGANI O, WALLEY BA, FLEMING GF, et al. Adjuvant exemestane with ovarian suppression in premenopausalbreast cancer: Long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol, 2023, 41 (7): 1376-1382.
[ 41 ] DAVIES C, PAN H, GODWIN J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stop-ping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet,2013,381 (9869): 805-816.
[ 42 ] CHUA BH, LINK EK, KUNKLER IH, et al. Radiation doses and fractionation schedules in non-low-risk ductalcarcinoma in situ in the breast (BIG 3-07/TROG 07. 01): A randomised, factorial, multicentre, open-label, phase 3study. Lancet, 2022, 400: 431-440.
[43 ] SHAITELMAN SF, ANDERSON BM, ARTHUR DW, et al. Partial breast irradiation for patients with early-stageinvasive breast cancer or ductal carcinoma in situ: An ASTRO clinical practice guideline. Pract Radiat Oncol, 2024,14: (2) 112-132.
[44 ] STRNAD V, POLGAR C, OTT OJ, et al. Accelerated partial breast irradiation using sole interstitial multicatheterbrachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol, 2023, 24 (3): 262-272.
[ 45 ]] OFFERSEN BV, ALSNER J, NIELSEN HM, et al. Partial breast iradiation versus whole breast irradiation for earlybreast cancer patients in a randomized phase I Trial: The Danish Breast Cancer Group Partial Breast IrradiationTrial. J Clin Oncol, 2022, 40 (36): 4189-4197.
[ 46 ] HAVILAND JS, OWEN JR, DEWAR JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials ofradiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomisedcontrolled trials. Lancet Oncol, 2013, 14 (11): 1086-1094.
[ 47 ] WHELAN TJ, PIGNOL JP, LEVINE MN, et al. Long-term results of hypofractionated radiation therapy for breastcancer. N Engl J Med, 2010, 362 (6): 513-520.
[ 48 ] WANG S, FANG H, HU C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-con-serving surgery in the modern treatment era: A multicenter, randomized controlled trial from China. J Clin Oncol,2020, 38 (31): 3604-3614.
[ 49 ] COLES CE, HAVILAND JS, KIRBY AM, et al. Dose-escalated simultaneous integrated boost radiotherapy in earlybreast cancer (IMPORT HIGH): A multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.Lancet, 2023, 401 (10394): 2124-2137.
[ 50 ] KUNKLER IH, WILLIAMS LJ, JACK WJL, et al. Breast-conserving surgery with or without irradiation in earlybrcast cancer. N Engl J Med, 2023, 388 (7): 585-594.
[ 51 WHELAN TJ, SMITH S, PARPIA S, et al. Omitting radiotherapy after breast-conserving surgery in luminal a breastcancer. N Engl J Med, 2023, 389 (7): 612-619.
[ 52 ] MANN GB, SKANDARAJAH AR, ZDENKOWSKI N, et al. Postoperative radiotherapy omission in selectedpatients with early breast cancer following preoperative breast MRI (PROSPECT): Primary results of a prospectivetw0-arm study. Lancet, 2024. 403 (10423): 261-270.
[ 53 ] WILD SR, MUNCK L, SIMONS JM, et al. De-escalation of radiorherapy after primary chemotherapy in cT1-2N1breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up ssults of a Dutch. prospective, registry study. LancetOncol, 2022, 23 (9): 1201-1210.
[ 54 ] KIM YB, BYUN HK, KIM DY, et al. Effect of elective intermal mammary node irradiation on disease-free survivalin women with node-positive breast cancer: A randomized phase 3 clinical trial. JAMA Oncol, 2022, 8 (1): 96-105.
[ 55 ] THORSEN LBJ, OVERGAARD J, MATTHIESSEN LW, et al. Intermal mammary node irradiation in patients withnode-positive carly breast cancer: Fifteen-ycar results from the Danish Breast Cancer Group Internal MammaryNode Study. J Clin Oncol, 2022, 40 (36): 4198-4206.
[ 56 ] TAYLOR C, DODWELL D, MCGALE P, et al. Radiotherapy to regional nodes in early breast cancer: An individualpatient data meta-analysis of 14 324 women in 16 trials. Lancet, 2023, 402 (10416): 1991-2003.
[ 57] ZHANG L, ZHOU M, LIU Y, et al. Is it beneficial for patients with pT1-2N1M0 breast cancer to receive postmas-tectomy radiotherapy ? An analysis based on Recurlndex assay. Int J Cancer, 2021, 149 (10): 1801-1808.
[ 58 ] JAGSI R, BARLOW WE, WOODWARD WA, et al. Radiotherapy use and incidence of locoregional recurrence inpatients with favorable-risk, node-positive breast cancer enrolled in the SWOG S1007 trial. JAMA Oncol, 2023, 9 (8):1083-1089.
[ 59 ] MURRAY BRUNT A, HAVILAND JS, WHEATLEY DA, et al. Hypofractionated breast radiotherapy for 1 weekversus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet, 2020, 395 (10237): 1613-1626.
[ 60 ] LAUGHLIN BS, CORBIN KS, TOESCA DAS, et al. Physician- and patient-reported outcomes of the MC1635phase 3 trial of ultrahypofractionated versus moderately hypofractionated adjuvant radiation therapy after breast-conserving surgery. Int J Radiat Oncol Biol Phys, 2024,118 (4): 1049-1059.
[ 61 ] MUTTER RW, GIRI S, FRUTH BF, et al. Conventional versus hypofractionated postmastectomy proton radiother-apy in the USA (MC1631): A randomised phase 2 trial. Lancet Oncol, 2023, 24 (10): 1083-1093.
[ 62 ] XIE J, XU F, ZHAO Y, et al. Hypofractionated versus conventional intensity-modulated radiation iradiation (HAR-VEST-adjuvant): Study protocol for a randomised non-inferior multicentre phase Il trial. BMJ Open, 2022, 12 (9):e062034.
[ 63] ZHAO X, FANG H, TANG Y, et al. POstmastectomy radioThErapy in Node-posiTive breast cancer with or withoutIntermal mAmmary nodaL iradiation (POTENTIAL): A study protocol for a multicenter prospective phase Ill ran-domized controlled trial. BMC Cancer, 2021, 21 (1): 1185.
[ 64 ] JIANG Z, WANG H, WANG S, et al. Chinese expert consensus statement on the clinical diagnosis and treatment ofbreast cancer bonc metastasis and bone related disease. Transl Breast Cancer Res, 2021, 2: 2.
[ 65 ] SWAIN SM, MILES D, KIM SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breastcancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.Lancet Oncol, 2020, 21 (4): 519-530. ,1 7
[ 66 ] MA F, YAN M, LI W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first linetreatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre,phase 3 trial. BMJ, 2023, 383: e076065.
[ 67 ] WARDLEY AM, PIVOT X, MORALES-VASQUEZ F, et al. Randomized phase I trial of first-line trastuzumab plusdocetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. JClin Oncol, 2010, 28 (6): 976-983.
[ 68 ] ROBERT N, LEYLAND-JONES B, ASMAR L, et al. Randomized phase II study of trastuzumab, paclitaxel, andcarboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast can-cer. J Clin Oncol, 2006, 24 (18): 2786-2792.
[ 69 ] YAN M, BIAN L, HU X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positivemetastatic breast cancer after trastuzumab and taxanes (PHENIX): A randomized, double-blind, placebo-controlledphase 3 study. Transl Breast Cancer Res, 2020, 1: 13.
[70 ] XU B, YAN M, MA F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment ofHER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Oncol, 2021, 22 (3): 351-360.
[ 71 ] MA F, OUYANG Q, LI W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastaticbreast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized, phase II study. J Clin Oncol,2019, 37 (29): 2610-2619.
[ 72 ] VERMA S, MILES D, GIANNI L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N EnglJ Med, 2012, 367 (19): 1783-1791.
[ 73 CORT SJ, KIM SB, CHUNG WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. NEngl J Med, 2022, 386 (12): 1143-1154.
[ 74 ] SAURA C, OLIVEIRA M, FENG YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive mctastatic breast cancer previously treated with ⩾2 HER2-directed regimens: Phase ll NALA Irial. J ClinOncol, 2020, 38 (27): 3138-3149.
[ 75 ] RUGO HS, IM SA, CARDOSO F, et al. Eficacy of margetuximab vs. trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol, 2021, 7 (4): 573-584.
[ 76 ] MURTHY RK, LOI S, OKINES A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastaticbreast cancer. N Engl J Med, 2020, 382 (7): 597-609.
[77 ] JI C, LI F, YUAN Y, et al. Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastaticbreast cancer after tyrosine kinase inhibitors treatment. Oncologist, 2023, 28 (10): e859-e866.
[ 78 ] HUA X, Bl XW, ZHAO JL, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment forpatients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002). Clin CancerRes, 2022, 28 (4): 637-645.
[79]边莉,徐兵河,邸立军,等.重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照IⅢ期临床研究.中华医学杂志,2020,100 (30):2351-2357.
[ 80 ] XU B, ZHANG Q, SUN T, et al. Efficacy, safety, and immunogenicity of HLXO2 compared with reference trastuzumabin patients with recurrent or metastatic HER2-positive breast cancer: A randomized phase Il equivalence trial. BioDrugs,2021, 35 (3): 337-350.
[ 81 ] BAJETTA E, PROCOPIO G, CELIO L, et al. Safety and efficacy of two different doses of capecitabine in the treat-ment of advanced breast cancer in older women. J Clin Oncol, 2005, 23 (10): 2155-2161.
[ 82 ] SEIDMAN AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Wil-liston Park), 2001, 15 (2 Suppl 3): 11-14. L
[ 83 ] ZELEK L, BARTHIER S, RIOFRIO M, et al. Weekly vinorelbine is an effective palliative regimen after failure withanthracyclines and taxanes in metastatic breast carcinoma. Cancer, 2001, 92 (9): 2267-2272.
[ 84 ] O'SHAUGHNESSY J, SCHWARTZBERG L, DANSO MA, et al. Phase ⅢI study of iniparib plus gemcitabine andcarboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J ClinOncol, 2014, 32 (34): 3840-3847.
[ 85 ] ROBSON ME, TUNG N, CONTE P, et al. OlympiAD final overall survival and tolerability results: Olaparib versuschemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative meta-static breast cancer. Ann Oncol, 2019, 30 (4): 558-566.
[86]孙春晓,王树森,李健斌,等.紫杉醇脂质体在晚期乳腺癌中应用的真实世界研究.中华肿瘤杂志,2023,45(1): 88-94.
[ 87] YUAN P, HU X, SUN T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastaticbreast cancer: A randomised clinical trial. Eur J Cancer, 2019, 112: 57-65.
[ 88 ] HU XC, ZHANG J, XU BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapyfor metastatic triple-negative breast cancer (CBCSG006): A randomised, open-label, multicentre, phase 3 trial. Lan-cet Oncol, 2015, 16 (4): 436-446.
[ 89 ] SIPOS O, TOVEY H, QUIST J, et al. Assessment of sructural chromosomal instability phenotypes as biomarkers ofcarboplatin response in triple negative breast cancer: The TNT trial. Ann Oncol, 2021, 32 (1): 58-65.
[ 90 ] XU B, SUN T, ZHANG Q, et al. Effcacy of utidelone plus capecitabine versus capecitabine for heavily pretreated,anthracycline and taxane-refractory metastatic breast cancer: Final analysis of overall survival in a phase Il ran-domised controlled trial. Ann Oncol, 2021, 32 (2): 218-228.
[ 91 ] BARDIA A, MAYER IA, VAHDAT LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negativebreast cancer. N Engl J Med, 2019, 380 (8): 741-751.
[ 92 CORTES J, RUGO HS, CESCON DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breastcancer. N Engl J Med, 2022, 387 (3): 217-226.
[ 93 ] JIANG Z, OUYANG Q, SUN T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negativebreast cancer: A randomized phase 3 trial. Nat Med, 2024, 30 (1): 249-256.
[ 94 ] ROBERTSON JFR, BONDARENKO IM, TRISHKINA E, et al. Fulvestrant 500 mg versus anastrozole 1 mg forhormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial. Lancet, 2016, 388 (10063): 2997-3005.
[ 95 ] FINN RS, MARTIN M, RUGO HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med, 2016,375 (20): 1925-1936. -3
[ 96 ] HORTOBAGYI GN, STEMMER SM, BURRIS HA, et al. Overall survival with ribociclib plus letrozole inadvanced breast cancer. N Engl J Med, 2022, 386 (10): 942-950.
[ 97 ] ZHANG P, ZHANG Q, TONG Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole oranastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast can-cer (DAWNA-2): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2023. 24(6): 646-657.
[ 98 ] TURNER NC, SLAMON DJ, RO J, et al. Overall survival with palbociclib and fulvestrant in advanced breast can-cer. N Engl J Med, 2018, 379 (20): 1926-1936.
[ 99 ] SLEDGE GW JR, TOI M, NEVEN P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in womenwith HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol,2017,35 (25): 2875-2884.
[ 100 ] ZHANG QY, SUN T, YIN YM, et al. MONARCH plus: Abemaciclib plus endocrine therapy in women with HR+/  HER2- advanced breast cancer: The multinational randomized phase ID study. Ther Adv Med Oncol, 2020, 12:  1758835920963925.
[ 101 ] XU B, ZHANG Q, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive andHER2-negative advanced breast cancer: A randomized, phase 3 trial. Nat Med, 2021, 27 (11): 1904-1909.
[ 102 ] SLAMON DJ, NEVEN P, CHIA S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormonereceptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase Ml ran-domized MONALEESA-3 trial: Updated overall survival. Ann Oncol, 2021, 32 (8): 1015-1024.
[ 103 ] JIANG Z, LI W, HU X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormonereceptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phasc 3 trial. LancetOncol, 2019, 20 (6): 806-815.
[ 104 ] YARDLEY DA, NOGUCHI S, PRITCHARD KI, et al. Everolimus plus cxemestane in postmenopausal patientswith HR (+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther, 2013, 30 (10): 870-884.
[ 105 ] KORNBLUM N, ZHAO F, MANOLA J, et al. Randomized phase II trial of fulvestrant plus everolimus or placeboin postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negativemetastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102. J Clin Oncol, 2018, 36 (16):1556-1563.
[ 106 ] WANDER SA, HAN HS, ZANGARDI ML, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitorprogression in breast cancer: A multicenter experience. J Natl Compr Canc Netw, 2021: 1-8.
[ 107 ] KALINSKY K, ACCORDINO MK, CHIUZAN C, et al. Randomized phase II trial of endocrine therapy withor without ribociclib after progression on cyclin-dependent Kinase 4/6 inhibition in hormone receptor-positive,human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN Trial. J Clin Oncol,2023, 41 (24): 4004-4013.
[ 108 ] YUAN Y, ZHANG S, WANG T, et al. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-basedtherapy after progression on palbociclib in patients with HR+HER2- MBC. Transl Breast Cancer Res, 2023, 4: 10.
[ 109 ] MODI S, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advancedbreast cancer. N Engl J Med, 2022, 387 (1): 9-20.
[110 ] RUGO HS, LEREBOURS F, CIRUELOS E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone recep-tor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre,open-label, non-comparative study. Lancet Oncol, 2021, 22 (4): 489-498.
[111 TURNER NC, OLIVERIRA M, HOWELL SJ, et al. Capivasertib in hormone receptor-positive advanced breastcancer. N Engl J Med, 2023, 388 (22): 2058-2070.
[ 112 ] YUAN Y, ZHANG S, WANG T, et al. Efficacy and clinical outcome of chemotherapy and endocrine therapy asfirst-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer. Chin MedJ (Engl), 2023, 136 (12): 1459-1467. 7
[ 113 ] RUGO HS, BARDIA A, MARME F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A ran-domised, open-label, multicentre, phase 3 trial. Lancet, 2023, 402 (10411): 1423-1433.
[ 114 ] SCHMID P, JUNG KH, WYSOCKI PJ, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as firstline (IL) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial  results from BEGONIA, a phase I b/ H study. Ann Oncol, 2022, 33 (S3): S199.
[115] YIN YM, WU XH, OU QC, et al. Efiacy and safety of SKB264 (MK-2870) fo previously treated metastatictriple negative breast cancer (mTNBC) in phase 2 study. Cancer Res, 2023, 83 (5_Supplement): OT1-03-02.
[116] ZHANG S, YIN Y, XIONG H, et al. Eficacy, Safety, and population pharmacokinetics of MW032 compared withdenosumab for solid tumor-related bone metastases: A randomized, double-blind, phase 3 equivalence trial. JAMAOncol, 2024: e236520.
[117] WANG T, CHEN J, YANG J,et al. CSCO expert consensus on the diagnosis and treatment o breast cancer brainmetastasis. Transl Breast Cancer Res, 2022, 3: 22.
[118] HURVITZ SA, MODI S, LI W, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with  HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast  (DB)-01,-02, and-03. Ann Oncol, 2023, 34 (S2): S335-S336.
[119] BARTSCH R, BERGHOF AS, FURTNER J, e al Trastuzumab deruxtecan in HER2-positive breast cancer withbrain metastases: A single-arm, phase 2 trial. Nat Med, 2022, 28 (9): 1840-1847.
[ 120 ] YAN M, OUYANG Q, SUN T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factorreceptor 2-positive breast cancer and brain metastases (PERMEATE): A multicentre, single-arm, two-cohort, phase2 trial. Lancet Oncol, 2022, 23 (3): 353-361.
[ 121] YANG Z, MENG J, MEI X, e al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-posi-tive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol, 2024: e235791.
[122]中国临床肿瘤学会,中华医学会血液学分会.葱环类药物心脏毒性防治指南(2013 年版).临床肿瘤学杂志,2013, 18 (10): 925-934.
[123]王碧芸,葛睿,江泽飞,等.乳腺癌靶向人表皮生长因子受体2酪氨酸激酶抑制剂不良反应管理共识.中华肿瘤杂志,2020, 42(10): 798-806.
[ 124 ] ZHENG Y, CAO WM, SHAO X, et al. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastaticbreast cancer: The PANDORA phase II trial. Nat Commun, 2023, 14 (1): 8314.
[125」葛睿,王碧芸,江泽飞,等.乳腺癌CDK4/6 抑制剂相关性不良反应管理共识.中华肿瘤杂志,2022,44(12):1296-1304.
[126]中国临床肿瘤学会(CSCO)淋巴瘤专家委员会,中国临床肿瘤学会(CSCO)乳腺癌专家委员会.西达本胺不良反应管理中国专家共识(2021年版).白血病·淋巴瘤,2021,30(9):518-523.
[ 127] LI J, WANG H, GENG C, et al. Suboptimal declines and delays in early breast cancer treatment after COVID-19quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020. EClinicalMedicine,2020,26:100503.
[ 128 ] ZHANG S, LI J, XU R, et al. Safety of COVID-19 vaccination in patients with breast cancer: Cross-sectional
[ 129 ] XU F, SEPULVEDA MJ, JIANG Z, et al. Effect of an artificial intelligence clinical decision support system ontreatment decisions for complex breast cancer. JCO Clin Cancer Inform, 2020, 4: 824-838.
[ 130 ] LI J, YUAN Y, BIAN L, et al. A comparison between clinical decision support system and clinicians in breast can-cer. Heliyon, 2023, 9 (5): e16059.